

## Gout: Diagnosis and Management Committee meeting 7

**Date:** 09/04/2021

**Location:** Video-conference via Zoom

**Minutes:** Final

<b>Committee members present:</b>		
Aung Soe		(Present for notes 1 – 4)
Ed Roddy		(Present for notes 1 – 4)
Alastair Dickson		(Present for notes 1 – 4)
Sam Finnikin		(Present for notes 1 – 4)
Jane Taylor		(Present for notes 1 – 4)
Kelsey Jordan		(Present for notes 1 – 4)
Hugh Gallagher		(Present for notes 1 – 4)
Hilton Hurst		(Present for notes 1 – 4)
Mohammed Rafiq		(Present for notes 1 – 4)
Luckshmana Jeyaseelan (Co-optee member)		(Present for notes 3c)

<b>In attendance:</b>		
Amber Hernaman	Project Manager, NGC	(Present for notes 1 – 4)
Julie Neilson	Senior Reviewer, NGC	(Present for notes 1 – 4)
Gill Ritchie	Guideline Lead, NGC	(Present for notes 1 – 4)
Audrius Stonkus	Research Fellow, NGC	(Present for notes 1 – 4)
Alexandra Bonnon	Health Economist, NGC	(Present for notes 1 – 4)
Sophia Kemmis Betty	Senior Health Economist, NGC	(Present for notes 1 – 4a)
Clifford Middleton	Guideline Commissioner, NICE	(Present for notes 1 – 4)
Ian Mather	Resource Impact, NICE	(Present for notes 1 – 4)

<b>Apologies:</b>	
Sarah Ryan	Committee Member

## 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the seventh guideline committee meeting on gout.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

## 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was

- Evidence review;
  - 4.2-4.4 In people with gout which urate lowering therapies are the most clinically and cost-effective for first and second line treatment.
  - 5.2 What is the best serum urate level target to use when treating to target in gout.
  - 6.2 What is the clinical and cost effectiveness of surgical excision of Tophi in people with gout.
- Protocols;
  - 2.2 What are the most accurate and cost-effective approaches to diagnosing gout

The Chair asked everyone to verbally declare any interests.

Name	Job title, organisation	Declarations of Interest	Type of interest	Decision taken
Hugh Gallagher	Consultant Nephrologist, SW Thames Renal Unit, Epsom and St Helier NHS Trust	Member of London CKD network steering group looking at CKD prevention in London for NHS	Non-financial professional and personal interest	No action required other than open declaration

The Chair and a senior member of the Developer's team noted that the interests

declared did not prevent the attendee from fully participating in the meeting.

### **3. Presentations, questions and discussion**

- a) Audrius Stonkus presented the evidence review 4.2-4.4 on ULT first and second line treatment. Alexandra Bonnon presented the health economics and edits were made to the recommendations on the day.
- b) Julie Neilson led the discussion and drafted protocol 2.2 Approaches to diagnosing gout
- c) Audrius Stonkus presented the evidence review 6.2 surgical excision of Tophi and edits were made to the recommendations on the day.
- d) Audrius Stonkus presented the evidence review 5.2 serum urate level target. Alexandra Bonnon presented the health economics and edits were made to the recommendations on the day.

### **4. Any other business**

None.

**Date of next meeting:** 21/05/2021

**Location of next meeting:** Video-conference